ArticleFrontiers in bioengineering and biotechnology2026
Histological fidelity and microenvironmental kinome signatures of metastatic patient-derived organoids.
Article in Frontiers in bioengineering and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Metastatic cancer remains the greatest clinical challenge due to ineffective treatments and limited reliable models for drug testing. Patient-derived organoids (PDOs) and their subsequent culture as patient-derived-organoid xenograft (PDOX) tumours have transformed cancer research by replicating the genetic and histological characteristics of primary tumours. However, less focus has been given to metastatic tumours. Here, we investigated how well kinase signalling was conserved in PDOs grown from core-needle biopsies isolated from metastatic tumour lesions of five cancer patients. We further compared changes in kinase signalling when these PDOs were grown as metastatic PDOX tumours in mice. Strikingly, PDOs retained much kinase signalling observed in the original tumour. Even more remarkable was the ability of the metastatic PDOX tumours to match both the signalling and morphological features of the original biopsy. Cross-sample analysis revealed lost Src Family Kinase signalling in PDO cultures, highlighting the important influence of the tumour microenvironment on signalling and demonstrating this can be partially restored in the
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.